Sprint Bioscience AB (publ) (STO:SPRINT)

Market Cap	429.45M +769.7%
Revenue (ttm)	153.28M +145.7%
Net Income	84.49M
EPS	0.82
Shares Out	105.52M
PE Ratio	4.94
Forward PE	13.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,384
Open	4.250
Previous Close	4.060
Day's Range	3.950 - 4.250
52-Week Range	0.476 - 4.590
Beta	-0.50
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 30
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPRINT

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error